Jeff Yass’s Terns Pharmaceuticals TERN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-521,571
| Closed | -$27.5M | – | 14515 |
|
|
2026
Q1 | $27.5M | Buy |
521,571
+513,974
| +6,765% | +$21.1M | ﹤0.01% | 1844 |
|
|
2025
Q4 | $307K | Buy |
+7,597
| New | +$176K | ﹤0.01% | 9893 |
|
|
2025
Q3 | – | Sell |
-87,623
| Closed | -$559K | – | 13860 |
|
|
2025
Q2 | $327K | Sell |
87,623
-3,551
| -4% | -$11.1K | ﹤0.01% | 10147 |
|
|
2025
Q1 | $252K | Buy |
91,174
+55,285
| +154% | +$226K | ﹤0.01% | 10456 |
|
|
2024
Q4 | $199K | Sell |
35,889
-9,989
| -22% | -$67.6K | ﹤0.01% | 10731 |
|
|
2024
Q3 | $383K | Buy |
45,878
+10,048
| +28% | +$82.7K | ﹤0.01% | 9089 |
|
|
2024
Q2 | $244K | Buy |
35,830
+16,087
| +81% | +$97.4K | ﹤0.01% | 9915 |
|
|
2024
Q1 | $130K | Sell |
19,743
-42,701
| -68% | -$279K | ﹤0.01% | 11030 |
|
|
2023
Q4 | $405K | Buy |
62,444
+23,338
| +60% | +$123K | ﹤0.01% | 9154 |
|
|
2023
Q3 | $197K | Sell |
39,106
-125,745
| -76% | -$798K | ﹤0.01% | 10248 |
|
|
2023
Q2 | $1.44M | Sell |
164,851
-163,177
| -50% | -$1.9M | ﹤0.01% | 5849 |
|
|
2023
Q1 | $3.88M | Buy |
328,028
+289,926
| +761% | +$2.77M | ﹤0.01% | 3837 |
|
|
2022
Q4 | $388K | Buy |
+38,102
| New | +$254K | ﹤0.01% | 8462 |
|
Other funds holding TERN
Jeff Yass's TERN Position: Q2 2026 in Review
Jeff Yass sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 521,571 shares — an estimated $27.5M sold.
Jeff Yass first reported a position in TERN in Q4 2022 and held it in 13 quarters. The position peaked at $27.5M in Q1 2026. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.
- Jeff Yass reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Jeff Yass sold 521,571 Terns Pharmaceuticals shares in Q2 2026, an estimated $27.5M.
- Jeff Yass first reported a position in Terns Pharmaceuticals in Q4 2022 and held it in 13 quarters.
- Jeff Yass's Terns Pharmaceuticals position peaked at $27.5M in Q1 2026.
- 1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.
Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.